Bradley Pharmaceuticals Inc Watch

from S-8 >50 pages Definitions Acp Test Safe Harbor Matching Contributions 1 Actual Deferral Percentage (Adp) 1 Adopting Employer 1 Adoption Agreement 1 Adp Test Safe Harbor Contributions 1 Aggregate Limit 1 Alternate Payee 1 Annual Additions 1 Annuity Starting Date 1 Applicable Life Expectancy 2 Average Contribution Percentage (Acp) 2 Basic Matching Contributions 2 Basic Plan Document 2 Beneficiary 2 Break in Eligibility Service 2 Break in Vesting Service 2 Code 2 Compensation 2 Contributing Participant 3 Contribution Percentage 4 Contribution Percentage Amounts 4 Deductible Employee Contributions 4 Defined Benefit Fraction 4 Defined Contribution Dollar Limitation 4 Defined Contribution Fraction 4 Determination Date 4 Determination Period 4 Direct Rollover 4 Directed Trustee 4 Disability 5 Discretionary Trustee 5 Distribution Calendar Year 5 Domestic Relations Order 5 Earliest Retirement Age 5 Early Retirement Age 5 Earned Income 5 Effective Date 5 Election Period 5 Elective Deferrals 5 Eligible Employee 5 Eligible Employer 5 Eligible Participant 6 Eligible Retirement Plan 6 Eligible Rollover Distribution 6 Eligibility Computation Period 6 Employee 6 Employer 6 Employer Contribution 6 Employer Money Purchase Pension Contribution 6 Employer Target Benefit Pension Contribution 6 Employer Profit Sharing Contribution 6 Employment Commencement Date 7 Enhanced Matching Contributions 7 Entry Dates 7 Erisa 7 Excess Aggregate Contributions 7 Excess Annual Additions 7 Excess Contributions 7 Excess Elective Deferrals 7 Fiduciary 7 Fiscal Year 7 Forfeiture 7 Fund 7 Highest Average Compensation 7 Highly Compensated Employee 7

from 10-Q ~20 pages Registration Rights Agreement

from 10-Q ~20 pages Registration Rights Agreement

from 10-Q ~10 pages Bradley Pharmaceuticals, Inc. and American Stock Transfer & Trust Company as Trustee First Supplemental Indenture Dated as of July 24, 2003 4% Convertible Senior Subordinated Notes Due 2013

from 10-Q ~50 pages Tia Section Indenture Section 310(a)(1) 7.10 (A)(2) 7.10 (A)(3) N.A. (A)(4) N.A. (B) 7.08; 7.10; 12.02 (C) N.A. 311(a) 7.11 (B) 7.11 (C) N.A. 312(a) 2.05 (B) 12.03 (C) 12.03 313(a) 7.06 (B)(1) N.A. (B)(2) 7.06 (C) 7.06; 12.02 (D) 7.06 314(a) 4.02 (B) N.A. (C)(1) 12.04 (C)(2) 12.04 (C)(3) N.A. (D) N.A. (E) 12.05 (F) N.A. 315(a) 7.01(b) (B) 7.05; 12.02 (C) 7.01(a) (D) 7.01(c) (E) 6.11 316(a)(last Sentence) 2.09 (A)(1)(a) 6.05 (A)(1)(b) 6.04 (A)(2) N.A. (B) 6.07 317(a)(1) 6.08 (A)(2) 6.09 (B) 2.04 318(a) 12.01

from 8-K ~10 pages Exhibit 10.31 Patents, Trademarks and Copyrights Security Agreement (Bradley)

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Nine Months Ended September 30, 2002 2001 Supplemental Disclosures of Cash Flow Information: Cash Paid During the Period For: Interest $ 67,000 $ 94,000 =========== ========== Income Taxes $ 3,245,000 $ 440,000 =========== ========== Supplemental Disclosures of Non-Cash Investing and Financing Activities: Acquisition of Fixed Assets Under Capital Leases and Financing Agreements $ 19,000 $ 453,000 =========== ========== See Notes to Condensed Consolidated Financial Statements 6

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Six Months Ended June 30, 2002 2001 Supplemental Disclosures of Cash Flow Information: Cash Paid During the Period For: Interest $ 50,000 $ 68,000 ============ =========== Income Taxes $ 2,173,000 $ 314,000 ============ =========== Supplemental Disclosures of Non-Cash Investing and Financing Activities: Acquisition of Fixed Assets Under Capital Leases and Financing Agreements $ 19,000 $ 380,000 ============ =========== See Notes to Condensed Consolidated Financial Statements 6

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Three Months Ended March 31, 2002 2001 Supplemental Disclosures of Cash Flow Information: Cash Paid During the Period For: Interest $ 20,000 $ 50,000 =========== =========== Income Taxes $ 443,000 $ 153,000 =========== =========== Supplemental Disclosures of Non-Cash Investing and Financing Activities: Acquisition of Fixed Assets Under Capital Leases and Financing Agreements $ 19,000 $ 279,000 =========== =========== See Notes to Condensed Consolidated Financial Statements 6

from 10QSB/A 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Nine Months Ended September 30, 2001 2000 Supplemental Disclosures of Cash Flow Information: Cash Paid During the Period For: Interest $ 94,000 $ 167,000 ========== ========== Income Taxes $ 440,000 $ 294,000 ========== ========== Supplemental Disclosures of Non-Cash Investing and Financing Activities: Acquisition of Fixed Assets Under Capital Leases and Financing Agreements $ 453,000 $ - =========== ========== See Notes to Condensed Consolidated Financial Statements 7

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Nine Months Ended September 30, 2001 2000 Supplemental Disclosures of Cash Flow Information: Cash Paid During the Period For: Interest $ 94,000 $ 167,000 ========== ========== Income Taxes $ 440,000 $ 294,000 ========== ========== Supplemental Disclosures of Non-Cash Investing and Financing Activities: Acquisition of Fixed Assets Under Capital Leases and Financing Agreements $ 453,000 $ - =========== ========== See Notes to Condensed Consolidated Financial Statements 6

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Six Months Ended June 30, 2001 2000 Supplemental Disclosures of Cash Flow Information: Cash Paid During the Period For: Interest $ 68,000 $ 94,000 =========== =========== Income Taxes $ 314,000 $ 162,000 =========== =========== Supplemental Disclosures of Non-Cash Investing and Financing Activities: Acquisition of Fixed Assets Under Capital Leases $ 380,000 $ - =========== =========== See Notes to Condensed Consolidated Financial Statements

from 10QSB 1 page Indenture or similar

from 10KSB 1 page Bradley Pharmaceuticals, Inc. and Subsidiaries Consolidated Statement of Shareholders' Equity Common Stock, Class B Common Stock, $.01 Par Value $.01 Par Value Shares Amount Shares Amount Balance at December 31, 1998 8,189,315 $14,761,947 431,552 $845,448 Stock Options Excercised 5,000 3,438 Shares Issued for Consulting Services 5,368 12,101 Purchase of Treasury Stock Distribution of Treasury Stock Registration Costs (18,475) Net Income for the Twelve Months Ended December 31, 1999 Balance at December 31, 1999 8,199,683 14,759,011 431,552 845,448 Stock Options Excercised 5,000 3,437 Shares Issued for Consulting Services 1,944 4,213 Warrants Issued for Consulting Services 15,262 Purchase of Treasury Stock Distribution of Treasury Stock (3,292) Net Loss for the Twelve Months Ended December 31, 2000 Balance at December 31, 2000 8,206,627 $14,778,631 431,552 $845,448 ========== ========== ======== ======== Retained Treasury Stock Earnings (Accumulated Shares Amount Deficit) Total Balance at December 31, 1998 373,933 $(560,883) $ (1,175,109) $13,871,403 Stock Options Exercised 3,438 Shares Issued for Consulting Services 12,101 Purchase of Treasury Stock 411,287 (570,182) (570,182) Distribution of Treasury Stock (18,795) 23,223 23,223 Registration Costs (18,475) Net Income for the Twelve Months Ended December 31, 1999 560,562 560,562 Balance at December 31, 1999 766,425 (1,107,842) (614,547) 13,882,070 Stock Options Excercised 3,437 Shares Issued for Consulting Services 4,213 Warrants Issued for Consulting Services 15,262 Purchase of Treasury Stock 25,000 (32,438) (32,438) Distribution of Treasury Stock (50,944) 95,060 91,768 Net Loss for the Twelve Months Ended December 31,2000 (2,062,832) (2,062,832) Balance at December 31, 2000 740,481$(1,045,220) $(2,677,379) $11,901,480 ========= =========== ========== ========== the Accompanying Notes Are an Integral Part of These Statements. F-6

from 4 1 page Indenture or similar

from 10KSB 1 page Bradley Pharmaceuticals, Inc. and Subsidiaries Consolidated Statement of Shareholders' Equity Common Stock, Class B Common Stock, $.01 Par Value $.01 Par Value Shares Amount Shares Amount Balance at December 31, 1997 8,174,295 14,653,927 431,552 845,448 Stock Options Excercised 10,000 11,388 Shares Issued for Consulting Services 5,020 9,798 Compensation Charge for Stock Options Issued to Consultants 86,834 Purchase of Treasury Stock, Net Net Income for the Twelve Months Ended December 31, 1998 Balance at December 31, 1998 8,189,315 14,761,947 431,552 845,448 Stock Options Excercised 5,000 3,438 Shares Issued for Consulting Services 5,368 12,101 Purchase of Treasury Stock, Net Registration Costs (18,475) Net Income for the Twelve Months Ended December 31, 1999 Balance at December 31, 1999 8,199,683 14,759,011 431,552 845,448 ========== ========== ======== ======== Retained Treasury Stock Earnings (Accumulated Shares Amount Deficit) Total Balance at December 31, 1997 146,088 (231,198) $ (2,094,082) 13,174,095 Stock Options Exercised 11,388 Shares Issued for Consulting Services 9,798 Compensation Charge for Stock Options 86,834 Purchase of Treasury Stock, Net 227,845 (329,685) (329,685) Net Income for the Twelve Months Ended December 31, 1998 918,973 918,973 Balance at December 31, 1998 373,933 (560,883) (1,175,109) 13,871,403 Stock Options Excercised 3,438 Shares Issued for Consulting Services 12,101 Purchase of Treasury Stock, Net 392,492 (546,959) (546,959) Registration Costs (18,475) Net Income for the Twelve Months Ended December 31,1999 560,562 560,562 Balance at December 31, 1999 766,425 (1,107,842) (614,547) 13,882,070 ========= =========== ========== ========== the Accompanying Notes Are an Integral Part of These Statements. F-6

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Nine Months Ended September 30, 1999 1998 Supplemental Disclosures of Cash Flow Information: Cash Paid During the Period For: Interest $ 105,000 $ 102,000 ========== ========== Income Taxes $ 202,000 $ 167,000 ========== ========== Supplemental Disclosures of Cash Flow Non-Cash Financing Activities: Acquisition of Fixed Assets Under Capital Leases $ 92,000 $ - ========== =========== See Notes to Condensed Consolidated Financial Statements 6

from 10QSB 1 page Bradley Pharmaceuticals, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Six Months Ended June 30, 1999 1998 Supplemental Disclosures of Cash Flow Information: Cash Paid During the Period For: Interest $ 97,000 $ 78,000 ========= ======== Income Taxes $ 196,000 $ 164,000 ========= ======== See Notes to Condensed Consolidated Financial Statements 6

from 10QSB 1 page Indenture or similar

from 10QSB 1 page Indenture or similar